GlobalData on MSN6d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
The American Journal of Managed Care8d
Fighting HIV Stigma: Empowering Global Leaders for Change
In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why ...
Team demonstrates unprecedented control of SIV replication with immune-based approach
Emory researchers are the first to show unprecedented control of SIV replication and decay of viral reservoirs by combining a ...
Science Daily6d
Targeted immune intervention and stopping ART in model of SIV infection leads to control of viral replication and reservoirs
Researchers have shown unprecedented control of SIV replication and decay of viral reservoirs by combining a stringent model of infection with the interruption of antiretroviral therapy (ART). The ...
St. Augustine doctor: HIV could end if ‘Big Pharma,’ health insurance weren't so greedy
Local family medicine physician weighs in on the continuing fight against HIV, and how drug companies and insurance providers ...
Merck study shows 33% reduction in cervical cancer deaths
Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.
infectiousdiseaseadvisor.com1d
Integrase Strand Transfer Inhibitor Use Linked to Higher Diabetes Risk
Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.
pharmaphorum7d
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment
Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.